This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

When cervical cancer returns or spreads after initial treatment, the outlook is often measured in months rather than years.

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data. The FDA approved bevacizumab-nwgd (Jobevne), a ...

Please provide your email address to receive an email when new articles are posted on . First-line anlotinib plus chemotherapy had noninferior PFS to bevacizumab plus chemotherapy for certain ...

National Institute for Health and Care Excellence (NICE) has recommended Lonsurf (trifluridine–tipiracil, Servier Laboratories) plus bevacizumab in final draft guidance for treating metastatic ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

Ovarian cancer comprises a group of different cancers that can form in the ovaries, fallopian tubes, or the peritoneum. For those patients within this population with aggressive disease, continuous ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

LOS ANGELES (Reuters) - Colorectal cancer patients who continued treatment with Roche Holding AG's Avastin even after their cancer worsened lived longer than those who went off the drug, according to ...

ORLANDO, Florida (Reuters) - A study of blockbuster drug Avastin in colon cancer patients who have undergone surgery showed that the drug's effectiveness wore off after patients stopped taking it, ...